The Shkreli Pill

In this episode, Martin makes a spontaneous $5,000 bet with a retail trader during a live stream and later announces his decision to step away from streaming. Before signing off, he shares key insights on covering short positions, highlighting the tactics and timing that separate disciplined execution from emotional trading.

In this episode, Martin reacts to Google’s unexpected announcement related to Quantum and examines its implications for the tech and AI sectors. He questions whether Charlie Munger’s long-held views on technology investing still hold up and evaluates Jim Cramer’s approach as a trader. Martin also provides an update on SPRB and how it fits into his current market outlook.

In this episode, Martin reveals that his portfolio is up 386% and breaks down the trades and strategies that led to this result. He discusses his positions in Beyond Meat (BYND), Natera, Bitcoin, and Quantum, explaining how each contributed to his performance and what he’s watching next in the market.

In this episode, Martin claims that the next GameStop-style setup has arrived and walks through what he calls his “perfect short” strategy. He analyzes the renewed surge in Beyond Meat (BYND) stock, exploring the mechanics behind the pump and outlining why he sees it as a prime opportunity for short sellers.

In this episode, Martin breaks down what he believes is the real reason behind the recent surge in Beyond Meat’s stock price. He also engages in a lively debate with members of the BYND community, examining differing perspectives on the company’s fundamentals, hype, and long-term viability.

In this episode, Martin comments on a surprising market trend involving Korean investors turning to Beyond Meat and argues that it could signal a market top. He also explores a potential new long position in RVMD (Revolution Medicines), analyzing its fundamentals and growth prospects.

In this compilation episode, Martin walks through historic and current market bubbles, focusing on the patterns he believes consistently appear right before they collapse. Using examples from past streams, he illustrates these warning signs and how he identifies them in real time while trading.

In this episode, Martin discusses his shift toward real estate investing and reflects on what that transition means for his trading journey. He also analyzes IDEAYA Biosciences, explaining why he views the stock as a promising long position and how it fits into his broader portfolio strategy.

In this episode, Martin discusses whether it still makes sense to hold Nvidia amid shifting market dynamics. He explores how energy markets are adapting to the growing demands of AI infrastructure and provides analysis of OKLO stock. The episode also touches on recent biotech stories that Martin views as potential scams.

In this episode, Martin humorously recounts the personal and financial stress of maintaining his margin account during the ongoing Quantum run. Blending candid storytelling with market commentary, he offers insight into the emotional side of trading under pressure.

In this episode, Martin reflects on the impact of the Quantum run on his portfolio and discusses how SPRB and CAPR have become his main remaining positions. He also shares insights on Bitcoin’s supply dynamics and offers his latest thoughts on JNJ and Atyr stocks.

In this highlight compilation, Martin showcases some of the funniest and most unexpected moments from his livestreams. Featuring quick wit, audience interactions, and the trademark banter that defines his streams, this episode captures the lighter side of Martin’s commentary and community exchanges.

In this episode, Martin debates a guest known as the “Motley Fool Guy,” whose reactions grow increasingly emotional as Martin challenges his arguments and investment logic. The exchange highlights contrasting perspectives on market optimism, valuation methods, and what it means to be a disciplined investor.

In this episode, Martin doubles down on his philosophy of shorting what he calls “fraud and hype” in the markets. The Capital Cycle Guy pushes back hard, leading to a heated debate over conviction, evidence, and the boundaries between skepticism and bias in trading.

In this episode, Martin is confronted by the “Capital Cycle Guy,” who challenges his short thesis in a tense and candid exchange. The discussion dives into differing views on market timing, capital allocation, and risk, offering a rare look at how contrasting investment frameworks collide in real time.

In this episode, Martin discusses his evolving thoughts on Applovin stock and the emotional challenges that can come with holding or trading it. He also outlines practical methods for testing and validating a technical analysis theory, focusing on how to separate intuition from data-backed strategy.

In this episode, Martin presents an in-depth analysis of AMD stock, breaking down the company’s fundamentals, valuation, and market position. He also examines the details behind AMD’s chip deal with OpenAI, clarifying what the agreement actually entails and how it might influence the company’s outlook.

In this episode, Martin explains why he believes Spruce stock still has room for further gains and discusses what makes rare disease drugs maintain profitability over time. He also outlines his short thesis on CAPR and the factors influencing that position.

In this episode, Martin outlines his next short trade, focusing on BTQ stock and the reasoning behind his position. He also takes a step back to explain the origins and mechanisms of enzyme replacement therapy, connecting scientific insight with market analysis.

In this episode, Martin explains why his prediction AI unexpectedly shifted to a long position on CAT stock and what factors may have driven the change. He also discusses his current view on QURE stock and shares additional book recommendations for investors interested in data-driven trading.

In this episode, Martin reflects on recent market losses and explains how he identified the setup that led to Spruce stock’s sevenfold increase. He also shares book recommendations that have influenced his thinking and offers career advice for aspiring investors and traders.

In this episode, Martin highlights what he describes as a breakthrough drug development and offers his forecast and analysis of its potential impact. He also takes a closer look at Spruce Biosciences stock, examining the factors that could shape its performance going forward.

In this episode, Martin examines a deal between OpenAI and AMD that he views as unusually suspicious, exploring its possible implications for the market. He also provides detailed analysis of Ambarella and Monopar Therapeutics, outlining the key factors shaping his outlook on both stocks.

In this episode, Martin presents a special “Best Of” compilation, revisiting key moments, insights, and lessons from previous streams. He highlights major themes and takeaways to help viewers prepare for what’s ahead in the market.

In this episode, Martin discusses why he believes shorting GPU providers could be the next major opportunity in the market and explores the factors driving that view. He also announces a competition with prizes for the best-performing Godel traders.